Halia Therapeutics Reports Strong Phase 2 Data for Ofirnoflast in Lower-Risk MDS, Appoints New CMO — Halia Therapeutics, Inc.

Event summary

Halia Therapeutics to present final Phase 2 data for ofirnoflast (HT-6184) at EHA2026, showing 67% hematological improvement and durable transfusion independence in lower-risk MDS patients.
Ofirnoflast demonstrated no treatment-related serious adverse events in the Phase 2 trial.
Halia appoints Han Myint, MD, FACP, as Chief Medical Officer to lead clinical development as ofirnoflast advances toward pivotal trials.
Dr. Myint brings over three decades of experience in hematologic malignancies and oncology drug development.

The big picture

Halia Therapeutics' positive Phase 2 data for ofirnoflast underscores the potential of targeting upstream innate immune biology in lower-risk MDS, a field with limited treatment options. The appointment of Han Myint as CMO strengthens Halia's clinical development capabilities as it prepares to advance ofirnoflast into pivotal trials. The company's focus on inflammasome-driven disease biology positions it to address significant unmet medical needs in hematologic diseases.

What we're watching

Clinical Development: Whether the robust Phase 2 data for ofirnoflast will translate into successful pivotal trials and regulatory approval.
Executive Impact: How Han Myint's extensive experience in hematologic malignancies and drug development will shape Halia's clinical strategy and pipeline progression.
Market Positioning: The pace at which Halia can differentiate ofirnoflast in the lower-risk MDS market, given the significant unmet need and competitive landscape.